Months after launching with lofty goal, Flagship startup streamlines ops, chops headcount
Even by Flagship Pioneering’s standards, the stated goal at Vesalius Therapeutics — unveiled at its launch this March — was exceedingly ambitious. Armed with $75 million in Series A funding, the startup was out to “revolutionize the treatment of the diseases that drive ninety percent of human illness.” It would, as CEO Christopher Austin explained, deploy cutting-edge technology to look for underlying causes for a dizzying array of common diseases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.